MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

21.41 166.63

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.03

Max

22.03

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+210.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-68M 504M
Ankstesnė atidarymo kaina	-145.22
Ankstesnė uždarymo kaina	21.41

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-20 23:43; UTC

Rinkos pokalbiai

Gold Consolidates; May Face Technical Correction -- Market Talk

2026-01-20 23:42; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

2026-01-20 23:41; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

2026-01-20 23:29; UTC

Rinkos pokalbiai

RBA Rate Hike in February Would Be a Painful One -- Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

2026-01-20 22:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

2026-01-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

2026-01-20 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

2026-01-20 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

2026-01-20 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

2026-01-20 22:18; UTC

Uždarbis

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

2026-01-20 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Live Events Are Boosting Retention, Co-CEO Says

2026-01-20 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

2026-01-20 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

2026-01-20 22:11; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

2026-01-20 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

2026-01-20 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

2026-01-20 22:07; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

2026-01-20 22:06; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

2026-01-20 22:00; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

ESG Roundup: Market Talk

2026-01-20 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

210.56% į viršų

12 mėnesių prognozė

Vidutinis 25 USD 210.56%

Aukščiausias 28 USD

Žemiausias 20 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.